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User perceptions of mental health consequences of 
hallucinogen use in self-identified spiritual contexts
Research report
Introduction
Hallucinogens are a controversial group of 
drugs to which a broad range of conflict-
ing health effects have been attributed.1 
They started out as promising candidates 
for psychiatric research in the late 1940s, 
and by 1965 over 2000 papers on the sub-
ject had been published (Sessa, 2005). 
Although methodologies were sometimes 
unpolished and results varied, lysergic 
acid diethylamide (LSD) therapy and 
similar techniques were applied to largely 
positive effect to a variety of psychological 
disorders. Particularly interesting were the 
results on treatment of addictions, with 
brief psychedelic therapy sessions often 
leading to consistent long-term recovery 
from alcoholism (Abramson, 1967).
However, the widespread recreational 
use of these drugs in the 1960s resulted 
in a number of highly publicised adverse 
health reactions, and further research on 
the hallucinogen class of drugs was pro-
hibited. This situation lasted until restric-
tions were gradually eased especially 
from the 1990s onwards, and the appear-
ance of a landmark study in 2006 inves-
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tigating the psychological and spiritual 
effects of psilocybin (the active ingredi-
ent of “magic mushrooms”) gave a new 
impetus to research in the field (Griffiths, 
Richards, McCann, & Jesse, 2006; Griffiths, 
Richards, Johnson, McCann, & Jesse, 2008; 
MacLean, Johnson, & Griffiths, 2011). In 
this study, thirty hallucinogen-naïve vol-
unteers received psilocybin or methylphe-
nidate hydrochloride as an active control 
in individual eight-hour sessions. Results 
were overwhelmingly positive, with par-
ticipants returning high scores on a mys-
ticism scale developed to assess primary 
mystical experiences, and with two-thirds 
furthermore scoring the psilocybin session 
as being among the top five most person-
ally meaningful experiences of their life-
time. Since then a number of studies have 
taken place in what now appears to be a 
healthy field of scientific endeavour.
The present interview study explores 
how users of hallucinogens in spiritual 
contexts perceive the consequences of 
their drug use, and seeks to understand 
the reasons why people choose to engage 
with these very powerful drugs and what 
changes such use incurs for their lives.2 
This will allow us to see positive and 
adverse consequences in the light of us-
age patterns, and to understand how us-
ers themselves seek to minimise adverse 
conditions. Hellman (2012) has called for 
qualitative studies into the life worlds of 
drug users as an important means of cus-
tomising solutions to recovery from such 
use, and in a broader sense such contex-
tualised insight can serve to inform cus-
tomised solutions to drug use on every 
societal level. Thus by providing in-depth 
perspectives on the mental health conse-
quences of hallucinogen use this paper 
aims to increase our understanding of 
the inherent complexity and ambiguity of 
these drugs, and thereby encourage more 
nuanced responses to their use.
Literature review
Clinical trials of hallucinogens in sub-
stance dependence are now once more 
being performed, although currently for 
the most part as pilot or proof-of-concept 
studies. Recently, such studies have sug-
gested the value of psilocybin in treating 
nicotine dependence (Johnson, Garcia-
Romeu, Cosimano, & Griffiths, 2014) and 
alcohol dependence (Bogenschutz et al., 
2015), the value of ibogaine in the treat-
ment of alcohol, cannabis, cocaine and 
crack dependence (Schenberg, de Castro 
Comis, Chaves, & da Silveira, 2014) and 
also the value of ayahuasca in treating al-
cohol, tobacco and cocaine dependence 
(Thomas, Lucas, Capler, Tupper, & Martin, 
2013). None of the studies discovered any 
clinically significant adverse reactions to 
the hallucinogenic treatment.
While larger controlled trials are neces-
sary to confirm these preliminary results, 
they are congruent with early findings on 
the therapeutic use of hallucinogens in 
the treatment of substance use disorders. 
A recent meta-analysis of single-dose LSD 
treatment of alcoholism in the 1960s re-
vealed significant therapeutic effect at 
short (two to three months) and medium 
(six months) periods post-treatment, 
but no significant effect in the long term 
(twelve months) (Krebs & Johansen, 2012).
Recent research has also obtained pre-
liminary evidence for the therapeutic ef-
fect of psilocybin (Grob et al., 2011) and 
LSD (Gasser et al., 2013) for anxiety in pa-
tients with life-threatening diseases. Both 
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studies discovered significant improve-
ments without serious adverse reactions 
after one or two hallucinogenic sessions.
It is difficult to understand how a few 
doses of hallucinogenic substances could 
have such positive therapeutic effect, and 
some have suggested that the efficacy of 
hallucinogens in the treatment of sub-
stance abuse stems from their reliable ca-
pacity of delivering transformative “peak 
experiences” that are similar in some ways 
to religious epiphanies (Strassman, 1995). 
In a recent review article, Majic´, Schmidt 
and Gallinat (2015) see evidence for thera-
peutic effect on both biological and expe-
riential levels, suggesting that the specifi-
cally hallucinogenic aspect of these drugs 
cannot be ignored in their administration 
as treatment.
With the rise of modern brain imaging 
techniques it has become possible to ob-
tain more specific knowledge of how hal-
lucinogenic drugs act on the brain. It has 
been known for quite a while that the clas-
sic hallucinogens mescaline, psilocybin 
and LSD all work by an agonist or partial 
agonist action on the serotonin 5-HT2A re-
ceptors (Iversen, Iversen, Bloom, & Roth, 
2009; Nichols, 2004), but it has also been 
commonly assumed that they “enhance 
excitatory neurotransmission and overall 
brain activity” (Lee & Roth, 2012, p. 1821). 
Research by Carhart-Harris, Erritzoe, and 
collaborators (2012) challenges this as-
sumption, finding that psilocybin caused 
“decreased activity and connectivity in 
the brain’s key connector hubs, enabling a 
state of unconstrained cognition” (p. 2138). 
Rather than causing the expected upsurge 
of possibly frivolous activity, psilocybin 
reduced activity in the default-mode net-
work, which earlier research has identified 
as implicated in a baseline mode of brain 
function (Raichle et al., 2001). It is worth 
mentioning that a relative deactivation of 
the default-mode network has also been 
discovered in experienced meditators both 
during the practice of meditation and in an 
ordinary resting state (Brewer et al., 2011).
Consistent with the finding by Carhart-
Harris, Erritzoe et al. (2012) is the discovery 
that psilocybin can have a defocusing ef-
fect on semantic networks that leads to “an 
increased availability of remote associa-
tions and thereby may bring cognitive con-
tents to mind that under normal circum-
stances remain non-activated” (Spitzer et 
al., 1996, pp. 1056–1057). Similarly, Petri 
et al. (2014) discovered significant aug-
mentations to the brain’s correlational net-
works in the psilocybin state, which they 
described as “a less constrained and more 
intercommunicative mode of brain func-
tion” (p. 8). This defocusing and altered 
state of connectivity may serve to explain 
some of psilocybin’s beneficial effect on 
people with diagnoses of alcoholism or de-
pression: their brains are normally “stuck 
in a rut” of narrow and repetitive cogni-
tive loops, and the drugs serve to remove 
such self-limiting restrictions for a period 
of time, thus enabling new perspectives. 
Some brain regions are activated more 
strongly under psilocybin, however, and 
Carhart-Harris, Leech, and collaborators 
(2012) found that this applies in particular 
to visual and other sensory regions, which 
can explain subjectively experienced in-
creases in the vividness of memories and 
may serve to facilitate autobiographical 
recollection in therapeutic sessions.
In recent years there has also appeared 
survey data on the users of hallucinogenic 
drugs outside of the laboratory. Carhart-
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Harris and Nutt (2010) obtained 600 re-
sponses which described LSD and psilocy-
bin as having a largely positive influence 
on the users’ well-being. Reported benefits 
included alleviating depression, anxiety 
and insomnia, as well as “improved in-
sight, perspective, self-understanding and 
acceptance, resolution of existential anxi-
eties, help with mourning and a reduced 
fear of death, improved optimism, self-es-
teem and an increased sense of spiritual-
ity” (p. 291). A large majority affirmed that 
they had had a spiritual experience while 
under the influence of a hallucinogen, and 
also felt that these drugs enabled them to 
access their “unconscious mind”. Minori-
ties of 14% (LSD) and 12% (psilocybin) 
of respondents commented on adverse 
effects and health risks, which included 
paranoia, panic attacks, psychotic symp-
toms, anxiety, and depression. A roughly 
simultaneous study with 667 respondents 
sought to investigate the differences be-
tween users of psychedelic drugs, users 
of other drugs and nonusers, and found 
that “the use of psychedelic drugs with a 
purpose to enhance self-knowledge is less 
associated with problems, and correlates 
positively with coping and spirituality” 
(Móró, Simon, Bárd, & Rácz, 2011, p. 188); 
it concludes with a call for further qualita-
tive investigations into these effects.
The field of qualitative studies remains 
however sparsely populated, and especial-
ly so with regard to hallucinogenic drugs, 
although some work on general drug use 
has implications also for users of halluci-
nogens. One important study in this regard 
is Aaslid’s (2007) in-depth interviews with 
Norwegian drug users, through which she 
identified three usage patterns that she la-
belled experimental, recreational and prob-
lematic. In explicit disagreement with offi-
cial narratives on illegal drug use, she em-
phasised the importance of distinguishing 
between these patterns of use, maintaining 
that neither experimental nor recreational 
users tended to end up as problem cases. 
Her perspective on distinct usage patterns 
is congruent with the findings of Kronbæk 
and Frank (2013), who interviewed adult 
cannabis users in Denmark and obtained 
evidence both of problematic and unprob-
lematic use, with the latter taking a rec-
reational form that did not interfere with 
social and economic life.
In attempting to comprehend the rea-
sons behind drug use, qualitative analyses 
sometimes perceive motivations relating 
to ritual and, at least implicitly, to religion. 
Sande (2000) has argued that the use of al-
cohol among youth can be understood as a 
rite of passage into adulthood, and Gauth-
ier (2004) interprets drug-fuelled rave par-
ties as displaced religious festivals. Such 
displacement of religious sentiment is 
central also to Aaslid’s (2008) understand-
ing of intoxication as a celebration of sub-
jectivity and inner experience serving as 
a countercultural defiance of the rigidity 
and mechanicalness of modern life: it is 
a turn from outward-looking materialism 
to the inward realm of the soul. Indeed, 
one of Aaslid’s (2009, p. 93) informants 
described her drug use as an aspect of a 
“deep spiritual quest”. In a similar vein, 
Sandberg and Tutenges (2015) interpret 
drug use as an encounter with the Djinn 
and dragons that live on the edges of our 
civilised worlds, outside the boundaries 
of sanity, reason, and other normative val-
ues.  “The excessively intoxicated charac-
ter is both an anti-hero, a loser incapable 
of doing anything right, and a hero, a Ni-
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etzschean Übermensch, who has the nerve 
and fortitude to stand up to established 
norms and rules” (Tutenges & Rod 2009, p. 
361; emphasis in original).
As is apparent from the above studies, 
the use of hallucinogenic drugs is pre-
dominantly related to positive effects at 
least by the users themselves. A minority 
of users also experienced various difficul-
ties as a consequence of their drug use, 
however, which is a result corroborated 
by a number of anecdotal reports espe-
cially in news media; a review of clinical 
cases of post-LSD psychosis is provided in 
Abraham, Aldridge, and Gogia (1996). In 
terms of brain damage and other forms of 
physiological damage, a review of 1960s 
and 1970s research on long-term adverse 
consequences of hallucinogen use discov-
ered no clear effects, although there were 
several reports of possible impairments 
that other studies failed to replicate. The 
review concluded that “the literature ten-
tatively suggests that there are few, if any, 
long-term neurophysiological deficits at-
tributable to hallucinogen use” (Halpern & 
Pope, 1999, p. 247). More recently, Nich-
ols (2004) has maintained that “[t]here is 
no evidence that any of the hallucinogens, 
even the very powerful semisynthetic LSD, 
causes damage to any human body organ” 
(p. 134). It might however be noted that 
hallucinogenic compounds that include 
monoamine oxidase inhibitors (MAOI) – 
particularly ayahuasca – may interact dan-
gerously with some other drugs and foods 
(dos Santos, 2013). Furthermore it is fre-
quently a problem that illegally produced 
drugs obtained on the black market are 
fake or impure and sometimes contain tox-
ic substances. While hallucinogenic drugs 
do seem to interact with dopaminergic 
neurotransmission to some degree, thus 
potentially sharing dependence-forming 
mechanisms with drugs such as cocaine 
and amphetamine, “there is no evidence 
of a withdrawal syndrome, and users do 
not appear to develop dependence” (Ivers-
en et al., 2009, p. 488).
The picture is somewhat less clear for 
adverse psychological effects. LSD has 
in some cases been found to induce both 
acute panic reactions and toxic psychoses 
(Iversen et al., 2009). Even with the very 
positive results reported by participants in 
the study by Griffiths et al. (2006), about 
one third of the participants nonetheless 
experienced periods of “significant fear” 
(p. 282). Psilocybin mushrooms have other-
wise been found to result in “only few and 
relatively mild adverse effects” in the Neth-
erlands (van Amsterdam, Opperhuizen, & 
van den Brink, 2011, p. 423), although the 
authors caution against occasional panic 
attacks and flashbacks. Participants in aya-
huasca ceremonies under the auspices of 
the Santo Daime Church in Oregon (Halp-
ern, Sherwood, Passie, Blackwell, & Rut-
tenber, 2008) and in Brazil (Bouso et al., 
2012) scored significantly lower on psycho-
pathology measures than control groups or 
the general population. A recent popula-
tion study by Krebs and Johansen (2013) in-
vestigated a sample of 130,152 adults from 
a United States National Survey on Drug 
Use and Health (NSDUH) that was con-
sidered representative of the general adult 
population, and of which 21,967 (16.9%) 
reported any lifetime prevalence of psy-
chedelic drug use. They found “no relation 
between lifetime use of psychedelics and 
any undesirable past year mental health 
outcomes, including serious psychological 
distress, mental health treatment […], or 
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symptoms of panic disorder, major depres-
sive episode, mania, social phobia, gener-
alized anxiety disorder, agoraphobia, post-
traumatic stress disorder, or non-affective 
psychosis” (p. 5). Indeed the effects tended 
toward the opposite, as psychedelic drug 
use correlated weakly with a low rate of 
mental health problems. The authors cau-
tion that these are effects at the population 
level, and may possibly mask adverse con-
sequences for some individuals counterbal-
anced by benign effects on others. Finally, 
in a study of over 190,000 adults from the 
same NSDUH database, Hendricks, Thorne, 
Clark, Coombs, and Johnson (2015) found 
that the use of classic psychedelics was as-
sociated with reduced psychological dis-
tress and suicidality.
While the above review indicates that 
hallucinogen use is not without psycho-
logical health risk, it does appear from ag-
gregated data that the benign consequenc-
es in this regard outweigh the adverse con-
sequences. This would seem to support 
the finding by Nutt, King, and Phillips 
(2010) that hallucinogens are, on a societal 
basis, the least harmful of all recreational 
drugs. As a variety of non-pharmacologi-
cal variables have been found to play an 
important role in the effects at least of 
psilocybin (Studerus, Gamma, Kometer, & 
Vollenweider, 2012), it might be suggested 
that careful attention particularly to the 
setting of hallucinogen use could reduce 
anxiety reactions.
Method
Design
Users of hallucinogenic drugs in spiritual 
contexts were interviewed either individ-
ually or in groups about the mental health 
consequences of their use. All communi-
cation was internet-mediated, and par-
ticipants were encouraged to interact with 
the interviewer via anonymised email ad-
dresses constructed specially for this pur-
pose. Participants therefore had the option 
of remaining unidentifiable even to the 
author of the study, which served to mini-
mise privacy concerns. Ethical approval 
was obtained from the Norwegian Social 
Science Data Services (reference 40281/3/
KH). Kvale and Brinkmann’s (2009) seven 
stages of interviewing – thematisation, 
planning, interviewing, transcription, 
analysis, verification, and reporting – were 
used as a structural basis for the study.
Recruitment
Participants were recruited from three dif-
ferent internet fora – one Norwegian, one 
frequented mainly by Europeans, and one 
American – devoted to the sharing and 
discussion of hallucinogenic drug expe-
riences, as well as one English-language 
forum concerned mainly with New Age-
type spirituality. Because of the varying 
emphases and membership groups, this 
set of fora allowed for a broad selection 
of hallucinogen users. Criteria for selec-
tion were adulthood and current or past 
hallucinogen use in self-identified spir-
itual contexts. Participation was based on 
voluntary response to recruitment letters, 
and took the form of individual (n = 5) or 
group (n = 11) interviews according to par-
ticipant preferences.
Basic demographic data were collected 
from participants in individual interviews 
and, where possible, from participants 
in group interviews. Participants in indi-
vidual interviews were all in their 30s or 
40s, and all male. Two were married with 
children, four held steady jobs in retailing, 
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education, music teaching and industrial 
services, and one was unemployed. All re-
ported stable living conditions in Western 
European or North American countries, 
with backgrounds in Christian or secular 
families. Participants in group interviews 
did not for the most part wish to volunteer 
any information of this kind; about half 
indicated their age and gender, and these 
were all male and between the age of early 
20s to middle 50s.
It should be noted that the recruitment 
process did not aim at obtaining a repre-
sentative set of participants reflecting the 
general population of hallucinogen users. 
Participants were required to volunteer for 
participation in response to recruitment 
letters posted on the internet, and users 
with some enthusiasm for hallucinogens 
were probably more likely to self-select for 
the study; it is certainly the case that users 
living on the streets or confined to hospital 
wards or prisons did not have the opportu-
nity to participate. In addition, every par-
ticipant who indicated gender was male. 
The study should therefore be taken to re-
flect the “best practices” of a generally re-
sourceful and predominantly male group 
of hallucinogen users.
Data collection
Interviews were conducted on a semi-
structured basis, with the aim of obtaining 
a naturally flowing conversation relating 
to a number of specific research questions. 
Participants in group interviews respond 
to a more restricted line of questions per-
taining mainly to one specific topic.
Typical questions used to guide the inter-
view.
•	Why	do	you	use	hallucinogenic	drugs?
•	Can	 you	 describe	 some	 hallucinogenic	
experiences	that	were	important	to	you?
•	How	do	you	feel	your	hallucinogen	use	
has influenced your life for better or 
worse?
•	Have	you	ever	felt	that	you	were	overdo-
ing	or	abusing	drugs?
•	Have	 you	 ever	 experienced	 healing	 of	
physical or psychological issues as a re-
sult	of	using	hallucinogenic	drugs?
Transcription and analysis
As interviews took the form of written 
communication, no transcription from 
oral records into writing was necessary. 
The obtained data were analysed using 
thematic analysis and Kvale & Brink-
mann’s (2009) procedure for meaning con-
densation. Themes were constructed on a 
basis of open-ended, exploratory and data-
driven comparative analyses of interview 
responses pertaining to all major research 
questions.
Due to the sensitive nature of the in-
formation, conversations on public fora 
are paraphrased in this report rather than 
quoted directly; this is intended to make 
testimonies less transparent to internet 
search procedures. Two interviews were 
conducted in Norwegian and are reported 
in translation. Statements have been edited 
for brevity and relevance to specific topics.
Results
Drug use
Participants reported use of a variety of 
psychoactive drugs. Most commonly re-
ported were the classic hallucinogens LSD 
and psilocybin (“magic mushrooms”), as 
well as cannabis, 3,4-methylenedioxy-
methamphetamine (MDMA, also known 
as “empathy” and “ecstasy”), ayahuasca, 
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and N,N-dimethyltryptamine (DMT). Sev-
eral participants also used a wide variety 
of more obscure drugs.
I prefer ayahuasca and kambo, with-
out forgetting psilocybin, LSA and the 
teacher San Pedro (ID1).
Many had passed through a period of ex-
cessive drug use in their youth, but were 
currently more careful with their use of 
hallucinogens. Most regarded about one 
trip per month as an acceptable frequency, 
although some were more restrictive. One 
participant quit all hallucinogens several 
years ago; all others were current users. 
None reported current usage of opiates or 
psychostimulants such as amphetamine 
and cocaine, but several had past experi-
ence with such drugs.
In the beginning I would use DMT at 
least once a week. Now 9 years into 
this I don’t have to go so often (ID15).
I use MDMA 3–4 times a year and psil-
ocybin mushrooms every autumn after 
a few days of picking – after a few trips 
one is satisfied till next year. LSD once 
a year or maybe a few times if I can get 
it, mescaline once or twice. 2-CB 4–5 
times a year on its own or with MDMA. 
At times I have a trip or two a month 
(ID17).
Most respondents were very careful about 
the setting for their hallucinogen session. 
Several have had experiences that turned 
bad because of a poor choice of setting, and 
emphasised in particular the need for a 
safe social environment consisting of peo-
ple they know and trust. A common theme 
especially for those participants who de-
scribed their past usage patterns as exces-
sive was that they used hallucinogens at 
parties. While some said they still enjoyed 
an occasional party, most preferred the 
company of close friends or solitude when 
using hallucinogenic drugs. Drug sessions 
took place in people’s homes or in nature.
Mostly I do mushrooms with a close 
friend who I have shared many experi-
ences with, so we don’t have to worry 
about each other when the trip peaks. 
Sometimes with a few beginners, but 
this is not my preference (ID12).
Before I would sometimes be at par-
ties, but now I’m almost always alone 
– in my home, or in nature (ID9).
Hallucinogenic drug sessions were not 
taken lightly. Some prepared their sessions 
weeks or even months in advance. Prac-
tical details were described as important, 
but so were the emotions and state of mind 
that one enters the session with. For this 
reason, many participants reported a cul-
tivation of positive mind-states in the pe-
riod leading up to the trip. This emphasis 
on set and setting has been part of the hal-
lucinogen subculture since the 1960s, and 
respondents often spoke about these mat-
ters with an almost pedagogical overtone: 
it appeared important to them to make oth-
ers understand that careful preparations 
are vital for a successful trip.
I usually plan my sessions in advance. 
I pick a day and make sure I am free 
that day and the next day. The best 
mood for hallucinogenic exploration is 
to be relaxed and to have a clear mind. 
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Make sure you do not have all kinds of 
worries on your mind. Also make sure 
that your physical surroundings reflect 
this calm state of mind. So not only 
clean out the junk in your head, but 
also the junk in your room where you 
are going to have your session (ID8).
Drug sessions are a kind of spiritual 
festival that I spend much time and 
energy preparing for, and afterwards 
contemplating and interpreting. I use 
especially the last week before the ses-
sion to practise meditation and be extra 
attentive to my dreams, sorting out my 
life, taking it easy. Actually my whole 
life is a preparation for the next ses-
sion – I try to be good, positive, helpful 
to others, avoiding negativity. By cul-
tivating positive feelings in my daily 
life I make myself ready for a good ses-
sion. For the session itself I set up a 
magic circle of protection, play some 
of my favourite music, burn incense. 
Sometimes reading spiritual literature 
is good to get in the mood (ID9).
I often get this feeling 1–3 months be-
fore the trip that “on that day I am go-
ing to trip, and I will take this much 
of this hallucinogen”. I’ve noticed that 
the times for my trips are usually when 
there has been a big change in my life – 
for example when I broke up with my 
boyfriend, or when I came back home 
after a long trip abroad (ID10).
Varieties of spiritual experience
Participants reported a wide range of spir-
itual experiences in their hallucinogenic 
drug sessions. Some rare sessions were 
described as truly transformative, with 
overwhelming emotions and a long-term 
impact on behaviour:
I experienced what we call ego death, 
an experience of my true self or soul. 
“Me” in its purest form, clear from all 
influence, learning and thought. I was 
who I always have been and always 
will be (ID12).
I was overwhelmed with a series of very 
deep psychedelic experiences, and was 
totally at a loss as to what I was sup-
posed to do with all I had received. At 
that point words began to form deep in 
my mind feeling like a message com-
ing from outside myself as if the mush-
room or nature was speaking directly 
to me. The message was: “Lead, be an 
example to others....” I broke down and 
cried like a baby, it was so beautiful I 
was completely overwhelmed with 
emotion. I will remember this for the 
rest of my life (ID15).
Other important sessions brought insight 
and understanding, and many supplied 
inner visions of strange events or worlds:
It is like to climb the mountain or con-
template heaven, and there you have 
the wisdom of the universe before your 
eyes... (ID1).
I perceive a “more real” level of reality 
underlying what we normally think of 
as “the” reality (ID9).
I came into a world of brilliant col-
ours and shapes, and insect-like, very 
strange beings (ID12).
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Meditation helps me get into a vision-
ary state when I am on mushrooms. I 
was trying to get into this state and I 
saw my spine turn into a tree. I became 
very calm. I felt my muscles relax and I 
felt very peaceful and in balance. This 
experience made me practise medita-
tion even more because I wanted to 
have such calmness in everyday life 
(ID8).
Spiritual experiences were also connected 
to feelings of love and friendship:
Mushrooms make me feel more em-
pathic and more understanding of the 
feelings and motivations of others. 
(ID8)
I took MDMA with some good friends, 
and we lay closely together in a bed. 
There was a moment when we all re-
alised that the love and warmth we 
felt for each other was real, and that 
we had chosen each other for this in-
teraction. We are all very good friends 
today, 12–13 years later (ID17).
Positive consequences
Respondents described a number of posi-
tive consequences of hallucinogen use for 
their lives. Many saw themselves as hav-
ing changed for the better because of the 
new perspectives the hallucinogen experi-
ences have afforded them. Some had taken 
up more healthy and ethical lifestyles that 
may include regular spiritual practice. 
They spoke of growth and self-develop-
ment, of dealing with fears and of renew-
ing their self-respect.
Hallucinogens have helped me to see 
the wonder in life, and I have felt re-
newed energy in my overall attitude 
and my studies. I feel very grateful for 
my family and for all those close to me. 
Life is good! (ID16).
One of the things these journeys have 
provided me with is a very deep level 
of self-introspection. I learned how to 
be with myself on a profound level and 
to understand myself in ways I never 
thought possible. This insight spreads 
outward like ripples in a pond: insight 
into the self becomes insight into other 
people which becomes insight into na-
ture and the world. It has eventually 
become an integral piece of a larger 
spiritual journey of self-improvement 
and growth (ID15).
I stopped drinking and smoking, and 
still do not drink and smoke. I started 
doing more workouts and eating more 
healthy food. The mushrooms made 
me feel more in tune with my body 
and that’s why I started living a more 
healthy life (ID8).
I now lead a full, healthy and medita-
tive life, and still use hallucinogens 
(ID14).
Mushrooms helped me to start seeing 
things “as they really are”, and to know 
myself. I feel more at one with the uni-
verse, the world and nature, and live 
more in the present. In connection 
with my increased feeling of oneness 
with nature I have also become more 
conscious of what I eat, particularly in 
relation to animal ethics (ID12).
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Hallucinogens have made me a calmer, 
more pleasant and more empathic hu-
man being (ID17).
Indeed, for some people these changes to 
their lives were the main purpose of engag-
ing with hallucinogenic drugs:
The time after the trip is the most im-
portant. It is more important than the 
time you spend tripping. Once you un-
derstand how the hallucinogens work, 
you will realise that the best time to 
make changes in your life is right af-
ter the trip. And then you just have to 
keep doing things in a new way. If you 
trip too often and change nothing, it is 
pointless (ID10).
It is sometimes hard to integrate these 
experiences, because they are so other-
worldly. Still they do have some clear 
implications for ordinary life. When 
you experience limitless, divine love 
then that says something about how 
you would like to live your life – al-
though it’s not so easy to express that 
love in the everyday world (ID9).
Among the most important changes to the 
participants’ lifestyles was the breaking 
out of addictions or habitual use of vari-
ous substances.
Thanks to ayahuasca I’ve stopped 
drinking every day, and thanks to kam-
bo and LSA I stopped smoking (ID1).
Recently I decided to take a much-
needed break from cannabis, which I 
attribute mostly to my use of halluci-
nogens (ID16).
With DMT and psilocybin there is, 
aside from the psychological “cleans-
ing”, a concrete physical feeling that 
accompanies spiritually transforma-
tive experiences. It feels like a men-
thol sensation all over my body. When 
I get this feeling, it is always accom-
panied by a major healing of my body 
and mind. For example, after a break-
through dose of smoked DMT, I was no 
longer addicted to Klonopin (ID20).
Hallucinogens were also experienced as a 
major contribution to the healing of other 
psychological and somatic illness:
I have been struggling with chronic fa-
tigue syndrome and fibromyalgia since 
my mid-twenties, for about fifteen 
years, to eventually end up in bed for 
five years. I lost everything: my career, 
many friends and my family. I only got 
better three years ago thanks to kambo 
and pharmahuasca [an ayahuasca varia-
tion]. The symptoms included low grade 
fevers that disappeared completely after 
few treatments; chronic sore throat and 
sinus congestion that are mostly gone; 
sleep problems that are significantly 
reduced; generalised body pain that is 
completely gone, and blurry vision and 
fog that are gone. I have tried almost all 
alternative methods over many years, 
but none gave me close to the success as 
did pharmahuasca (ID18).
While none of the participants claimed to 
understand exactly how this healing effect 
takes place, they indicated two possible 
healing mechanisms: one physiological, 
and one related to the experience itself of 
intense joy and spiritual connection.
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DMT and psilocybin are the reason I 
stopped taking antidepressants. The 
medication attaches itself to the same 
receptors as DMT does, so I skipped 
a dose deliberately in order to take 
DMT unaffected by it. The next night 
I did the same thing, and by the third 
day I no longer felt the need to take 
antidepressants, and haven’t since. 
The problems have never returned. 
I started to feel like a human being 
again, and with semi-regular DMT 
and psilocybin use, both my opiate 
and alcohol abuse rapidly declined 
and vanished. It was more than just 
transformative on a personal level – 
there must also have been a physi-
ological effect (ID14).
I believe it has something to do with 
the serotonin that is released, but also 
with how positive the experience is, 
and with that feeling of total freedom 
from worry that one can experience 
and carry into daily life. It is also help-
ful to have shared a moment of com-
plete joy with close friends (ID17).
Adverse consequences
One of the potential dangers of using hal-
lucinogenic drugs is that one can have 
difficult, scary and perhaps damaging 
experiences. Many participants had been 
through such “bad trips”, but most of these 
tended to think of them as difficult learn-
ing experiences that have valuable long-
term impact:
I have had challenging experiences and 
I learnt a lot from them. Not only did I 
learn how to avoid mistakes that can 
lead to a bad trip, but most of all I start-
ed to know more about myself. When 
you have a hard time on hallucinogens 
it can feel like you are dying, and when 
you think you are dying you may dis-
cover aspects of yourself that you never 
paid attention to. You discover what is 
important in your life. For me a suc-
cessful mushroom experience is one 
where I say to myself: “this is so in-
tense, why do I do this to myself. I am 
never going to do this again.” Of course 
I always do it again at some point (ID8).
It should be noted however that some of 
these learning experiences were experi-
enced as truly hellish, causing difficul-
ties for several years. This is one reason 
why users of hallucinogenic drugs advised 
that sessions are carefully prepared, as de-
scribed above. When bad situations did 
arise, many participants attempted to deal 
with them through the use of various spir-
itual techniques such as deep breathing, 
meditation and chanting:
How	 do	 I	 deal	 with	 bad	 trips?	 With	
calmness, with breathing, with the 
knowledge that they are already ex-
ceeded situations (ID1).
Accept what you get. Observe it. Good 
or bad, whatever it is. Have you got 
negative	 emotions?	 Observe	 them.	
How	do	they	feel?	Take	them	as	tools	
to learn something. Be grateful for eve-
ry difficult trip because they are the 
ones that teach you the most (ID10).
Several participants acknowledged a po-
tential for overdoing hallucinogens, and 
some cautioned against the spiritual and 
psychological consequences of overuse:
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Possible consequences of overdoing 
hallucinogens are to feel the ego spir-
itualised, omnipotent, or enlightened, 
or to go crazy, or live in fear. Such 
overuse doesn’t destroy egoism but 
rather increases it (ID1).
Many also pointed out that there is some-
thing of a fail-safe mechanism in the use of 
hallucinogens, as the positive drug effects 
tend to diminish with repeated use. Hal-
lucinogens are for this reason subject to a 
natural self-regulation that counteracts 
long-term abuse:
I was tripping on LSD 4–5 times a 
week for 3–4 months. What happened 
was that I lost the trips – I no longer got 
into the psychedelic mind state (ID10).
It is possible to develop a kind of de-
pendency, but MDMA is very self-reg-
ulating in that if you take it more than 
a few days in a row, it simply doesn’t 
work like it used to. For this reason use 
tends to limit itself, which is one of the 
reasons why I think MDMA is among 
the safest drugs of all (ID17).
Probably the greatest danger with halluci-
nogen use is that it could lead to lasting 
mental health problems. While several 
participants reported temporary experi-
ences of mental chaos and confusion while 
under the effect of hallucinogens – some-
thing that might be termed a “bad trip” 
– only a few described long-term conse-
quences of this kind.
Ayahuasca was beautiful to me. 
Opened my mind – but led to mental 
disorders. I had trouble closing down 
my third eye and staying grounded 
when I came down from it (ID2).
One respondent ended up in a short-term 
psychiatric ward with what his doctors 
thought was a toxic psychosis. He accept-
ed that he sometimes had difficulties with 
remaining grounded, but was agnostic as 
to whether this is because he has a mental 
illness or if it is simply a natural but un-
fortunate consequence of his shamanistic 
practice:
If I were a member of a more open-
minded culture, where the ancient art 
of Shamanism is accepted, I would 
probably have been congratulated for 
becoming the tribe’s latest Shaman. If I 
had this experience whilst living with 
people who are highly experienced 
with altered states-of-consciousness, 
then the outcome may well have been 
quite different, and I would probably 
not have ended up a prisoner of the 
system (ID5).
Discussion
We have explored how some users of hal-
lucinogenic drugs describe the character-
istics of, reasons behind and consequences 
of their drug use. What has emerged is a 
picture of mature males with stable homes 
and jobs using hallucinogens in occasion-
al, well-prepared spiritual settings for the 
purpose of gaining insight into themselves 
and their worlds. Some have a past of quite 
unrestrained drug use at parties, but have 
since moved away from excessive use. We 
see here evidence of a learning curve or ca-
reer for hallucinogen users, starting with 
youthful experimentation and ending with 
more conscious, moderate and carefully 
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planned use as an integrated aspect of a 
stable adult life. The respondents’ descrip-
tions of intoxication in spiritual terms is 
unsurprising since such a context was 
presented as a criterion for participation, 
but does suffice to demonstrate that spirit-
ually-inclined hallucinogen users do exist 
and are available to researchers. Whether 
the usage pattern here reported can be 
termed “recreational” in line with Aaslid’s 
(2007) terminology is perhaps debatable, 
but it certainly seems well removed from 
what she labels a “problematic” pattern 
of use. Several participants describe their 
intoxication experiences as journeys or 
other cognates of adventure, thus fram-
ing their drug use in mythological terms 
reminiscent of “the hero’s journey” or 
“the journey to the underworld”. These 
archetypal terms support the perceived 
transformative potential of these practices, 
and is understood by researchers such as 
Aaslid (2007) and Sandberg and Tutenges 
(2015) to reveal an important motivation 
for drug use: in an otherwise sanitised and 
commoditised modern world, drugs may 
be the last remaining resort for would-be 
explorers of wild and unknown lands.
Like most people, the participants carry 
with them a variety of mental health is-
sues, and they use hallucinogens partly in 
order to work on themselves and perhaps 
heal these personal problems. From their 
perspective, hallucinogen use has resulted 
in a broad range of positive personality 
and lifestyle changes, including a new-
found or strengthened interest in spiritual 
ideas and practices. They confirm the pos-
sibility of temporary adverse effects such 
as acute panic reactions (van Amsterdam 
et al., 2011), but are generally not afraid to 
encounter problematic psychological ma-
terial in their drug sessions. Indeed, they 
often regard such sessions as challenging 
and valuable learning experiences. We can 
probably understand their openness to the 
value of “bad trips” in terms of their ma-
turity: most participants now have long 
experience with hallucinogens and have 
learnt to deal with and profit from chal-
lenging situations. This knowledge also 
includes how to plan their drug sessions 
so as to minimise problems.
Because hallucinogenic drugs tend to 
lose their most valued effects with over-
intensive use, participants regard the de-
pendence potential of these drugs as fairly 
slight, which supports earlier research on 
the low dependence-forming potential of 
hallucinogens (Iversen et al., 2009). On the 
other hand, they claim that their use of hal-
lucinogens has facilitated the breaking out 
of habitual use of other drugs. The promis-
ing effects of hallucinogens especially on 
substance dependence that is indicated 
both by older research from the 1960s and 
several recent clinical trials (Bogenschutz 
et al., 2015; Johnson et al., 2014; Schen-
berg et al., 2014; Thomas et al., 2013) are 
thus corroborated by the participants of 
this study, who furthermore perceive both 
biological and transformative-experiential 
aspects to these healing processes.
As in the study by Carhart-Harris and 
Nutt (2010), participants generally report 
a broad range of health benefits from their 
hallucinogen use, although with a minor-
ity of 10–15% having incurred significant 
adverse mental health effects. Two of six-
teen participants have experienced seri-
ous mental health problems that may re-
sult from their drug use, although one of 
these maintains that the real problem is 
that the psychiatric establishment tends to 
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misdiagnose spiritual or shamanic experi-
ences as psychotic. Based on the informa-
tion received in the interviews, there is no 
easy way to explain why their trajectories 
diverge from those of the majority. It might 
however be significant that both were re-
cruited from a web forum devoted primar-
ily to the discussion of New Age spiritual-
ity rather than hallucinogen use.
With their narratives of difficulty and 
hospitalisation, these two participants re-
mind us that hallucinogen use can never be 
considered a safe practice. Described com-
monly as a journey into the unknown, a 
hallucinogen session seems to involve fre-
quent confrontations with dragons and oth-
er denizens of the dark, and it should not 
surprise us that not everybody will emerge 
unscathed from such encounters. Yet as the 
majority of the participants in this study 
have insisted, such adventures have a num-
ber of positive consequences as well, even 
if they are at times overly intense; indeed, 
for experienced and adaptable adventurers, 
these challenging confrontations might be 
the most valuable of all.
We cannot generalise from these results, 
and must remember that the narratives 
here have emerged from predominantly 
male respondents who self-selected for 
participation. It would not be surprising 
if their motivation was based in large part 
on an enthusiasm for hallucinogen use. 
The aim of qualitative research is in any 
case not to be generalisable, but to ob-
tain insight into individual experiences 
(Wright et al., 2015). As far as the inter-
view reports are broadly congruent with 
more representative studies, which here 
seems to be the case, a probable relation to 
a broader segment of the population is in-
dicated. Thus the qualitative study can be 
used to contextualise and deepen the more 
representative but less intensive findings 
provided by quantitative survey data and 
similar methodologies.
The strength of qualitative studies is 
therefore to provide thick descriptions of 
participant life worlds that allows us to 
understand more clearly why and through 
what mechanisms given effects take place. 
Thus we have gained from this study a per-
spective on why hallucinogen addiction 
is not a significant problem, and we have 
learnt to understand bad trips as learning 
experiences. We have seen an outline of 
a hallucinogen career path and at least a 
perceived relation between hallucinogen-
induced spiritual experiences, changes in 
personality and lifestyle, and the healing 
of long-standing health issues.
In sum, this study has obtained evidence 
of a group of hallucinogen users that rarely 
feature in the news media. While their re-
ports are not representative of hallucino-
gen users in general, they do exemplify 
an important segment of such users that is 
otherwise largely invisible in Western so-
cieties – in Fuller’s (2000, p. 7) terminol-
ogy, a “religious underground”. It should 
probably be worthwhile to obtain further 
insight into this clandestine spiritual sub-
culture that most Western societies have 
outlawed without first taking the effort to 
understand.
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